Sagimet Plans Move To Phase III In NASH By Year-End

 
• By Joseph Haas

Sagimet reported positive Phase IIb data for denifanstat in non-alcoholic steatohepatitis that may place the once-daily, oral drug as a serious competitor in a disease that at present has no approved drug therapy.

Fatty liver
Sagimet is looking to take its NASH candidate into Phase III later this year • Source: Shutterstock

More from Clinical Trials

More from R&D